For decades, the pharmaceutical industry has been locked in an expensive, time-consuming cycle of iterative development. Formulation scientists, tasked with perfecting the release profiles of complex drugs—such as long-acting injectables and implants—have relied heavily on the "try, test, and make again" cycle. In this conventional paradigm, a single dissolution study can stall a program for 30 to 90 days. If the results fail to meet the target, the clock resets, leading to millions of dollars in potential losses and significantly postponed regulatory filings.
However, a new frontier in digital drug development is emerging. By leveraging advanced imaging and machine-learning-driven "microstructure intelligence," companies like DigiM Solution are turning the hidden, internal architectures of drug doses into highly accurate, predictive roadmaps. Ahead of his keynote at the upcoming PharmSci 360 conference in New Orleans, DigiM CEO Shawn Zhang, Ph.D., explains how looking inside the dose is transforming the industry from reactive testing to proactive design.
The Hidden Variable: Why Surface Appearance Deceives
The fundamental challenge in drug formulation is that two seemingly identical products can behave in diametrically opposed ways. To the naked eye, or even under standard scanning electron microscopy, two batches of microspheres may appear to have the same particle size and external morphology. Yet, their dissolution profiles—how quickly they release their active pharmaceutical ingredient (API)—often differ wildly.
"From the outside, two products can look the same, but once you open them up, you see the primary particles are deposited differently because of different process conditions," Zhang explains. This "hidden variable" is the internal spatial distribution of the API, excipients, and pore space.
In a notable joint study with the University of Connecticut and the FDA, researchers examined PLGA (poly(lactic-co-glycolic acid)) microspheres. They discovered that variations in stir rate and silicone oil viscosity during manufacturing created distinct internal architectures. One batch was uniform, while the other was "patchy," with regions void of both API and porosity. Conventional bulk testing failed to capture these nuances, but advanced imaging revealed that the manufacturing process change—invisible to standard assays—was the primary driver of the unexpected release profile.
A Chronology of Innovation: From Microscopy to Digital Twin
The evolution of this field follows a clear trajectory of increasing resolution and digital integration:
- Pre-2014: The industry relied almost exclusively on bulk dissolution testing. This required large quantities of active ingredients, often making early-stage development prohibitively expensive, as the drug substances were "literally more expensive than gold."
- 2014–2020: DigiM and other pioneers began utilizing focused ion beam scanning electron microscopy (FIB-SEM). This allowed for 3D reconstruction of microstructures by milling away thin layers and imaging each cross-section.
- 2021–2024: The introduction of generative AI and advanced computational modeling allowed researchers to move beyond just seeing the microstructure to predicting how it would behave.
- 2024–Present: Regulatory bodies, including the FDA, have begun incorporating these imaging-based characterization methods into draft guidance, signaling a paradigm shift toward "microstructure intelligence" as a formal component of bioequivalence.
Supporting Data: The Power of Predictive Modeling
The core of this revolution is the ability to transform grayscale, 2D microscopy images into high-fidelity 3D digital maps. This process, known as semantic segmentation, allows software to identify and label individual phases—such as API particles, polymer matrices, and air-filled pores—using convolutional neural networks.
Once the "digital map" is constructed, the simulation models how the drug will release in real-time. Unlike traditional platforms that require historical dissolution data to calibrate models, DigiM’s ivisLab platform uses the physical microstructure as an initial condition.
"The major difference is that this approach does not require any prior testing data," Zhang notes. By factoring in physical variables like solubility, media pH, and diffusion coefficients, the software simulates how the API finds its way out of the matrix. The model accounts for "percolation"—a concept similar to the distribution of chocolate chips in a cookie. If the API is connected in a continuous network, it releases differently than if it exists as isolated "islands" within an excipient.
This generative capability was highlighted in a 2024 Nature Communications study. Researchers generated virtual tablet microstructures to identify the exact percolation threshold of microcrystalline cellulose. By validating these virtual models against physical samples, they proved that they could predict the behavior of a 20% formulation by training the model on 10% and 30% variants, effectively eliminating the need for intermediate "wet lab" manufacturing campaigns.
Official Responses and Regulatory Trajectories
The FDA’s engagement with this technology underscores its growing importance in ensuring product quality and safety. Regulatory science projects have increasingly focused on whether microstructure characterization can serve as a legitimate surrogate for expensive clinical studies.
Two recent draft guidances from the FDA exemplify this shift:
- Minocycline Hydrochloride (November 2025): The FDA proposed an in vitro alternative to comparative clinical endpoint studies for generic extended-release powders, explicitly calling for the characterization of porosity and spatial distribution using orthogonal methods.
- Dexamethasone Ophthalmic Inserts (May 2026): This guidance lists microstructure imaging as a mandatory comparative study, identifying the spatial distribution of drug particles and pores as "critical quality attributes."
By citing research co-authored by private firms like DigiM, the agency is signaling that as long as the data integrity is robust, the industry can rely on these "digital twins" to support regulatory submissions.
Implications for the Future of Pharma
The shift toward microstructure intelligence holds profound implications for the pharmaceutical pipeline:
1. Cost and Material Efficiency
Early-stage drug substances are costly. Traditional dissolution studies consume grams of material; the imaging-based workflow requires only a few milligrams—or just a handful of particles. This efficiency allows for faster screening of potential formulations, enabling companies to fail fast or optimize early.
2. De-risking Regulatory Filings
By providing a clear, evidence-based view of why a drug behaves the way it does, companies can build a more robust "totality of scientific evidence" for regulators. This transparency reduces the risk of rejection or requests for additional, time-consuming studies during the review process.
3. Precision Engineering of Delivery
Generative AI allows scientists to work backward. If a target release profile is required for a specific therapeutic outcome, scientists can now use AI to determine the necessary internal architecture to achieve it. Instead of "testing until it works," they can "design until it is optimal."
4. A New Standard for Data Integrity
As Zhang emphasizes, "Eventually, no client and no regulator makes decisions based on just images." The future of the industry lies in the digital infrastructure—the protocols for sample preparation, the quality controls, and the rigorous management of data. Images are merely the raw material; the true value lies in the transformation of those images into quantifiable, actionable, and defensible data.
Conclusion
As the industry prepares for PharmSci 360, the message from leaders like Dr. Shawn Zhang is clear: the era of "guess and check" in formulation development is drawing to a close. By bridging the gap between high-resolution physical imaging and advanced machine learning, the pharmaceutical industry is gaining an unprecedented view inside the dose. This evolution promises not only to reduce the financial burden of drug development but, more importantly, to accelerate the delivery of safe, effective, and precisely engineered medicines to patients worldwide.
The path forward is no longer about testing more samples; it is about understanding the ones we have at a molecular, structural, and digital level.
About the Author
